Drug Trial Radar · NCT05529316
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
150
Actual
Start
Dec 12, 2022
Primary completion
Apr 27, 2026
Study completion Apr 27, 2026
Sponsor
- Lead sponsor
- Agenus Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, 2-part, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma refractory to checkpoint inhibitor therapy.
Conditions
- Advanced Melanoma
Interventions
BotensilimabDrug
An anti-CTLA-4 monoclonal antibody
BalstilimabDrug
An anti-PD-1 monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response RateTime frame: Up to 40 months
Locations
51 sites in 10 countries. Site status is shown where the registry gives one.
Scottsdale Healthcare Hospitals DBA HonorHealth
Scottsdale, Arizona
Virginia K. Crosson Cancer Center at St. Jude Medical Center
Fullerton, California
Providence Saint John's Health Center
Santa Monica, California
Yale University School of Medicine - Yale Cancer Center
New Haven, Connecticut
Georgetown University Medical Center
Washington D.C., District of Columbia
Dana-Farber Cancer Institute
Boston, Massachusetts
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
Universitair Ziekenhuis Brussel
Jette, Belgium
Oncosite - Centro de Pesquisa Clinica Em Oncologia
Ijuí, Brazil
Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho
Jaú, Brazil
Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa
Porto Alegre, Brazil
INCA II - Instituto Nacional de Cancer Jose Alencar Gomes da Silva
Rio de Janeiro, Brazil
Hospital Sirio Libanes
São Paulo, Brazil
Real e Benemerita Associaçao Portuguesa de Beneficencia - A Beneficencia Portuguesa de Sao Paulo
São Paulo, Brazil
Hospital A.C. Camargo Cancer Center
São Paulo, Brazil
CHU Amiens Picardie - Hopital Sud
Amiens, France
CHU Grenoble-Alpes - Hopital Michallon
La Tronche, France
Centre Leon Berard
Lyon, France
CHU de Nantes
Nantes, France
AP-HP Hopital Saint-Louis
Paris, France
Centre Eugene Marquis
Rennes, France
Gustave Roussy
Villejuif, France
Universitaetsklinikum Essen
Essen, Germany
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany
Universitaetsklinikum Heidelberg
Heidelberg, Germany
University Hospital Schleswig-Holstein
Kiel, Germany
Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz
Mainz, Germany
Klinikum der Universitaet München
München, Germany
Universitaetsklinikum Tuebingen
Tübingen, Germany
Universitaetsklinikum Würzburg
Würzburg, Germany
IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l.
Meldola, Italy
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Naples, Italy
Azienda Ospedaliero Universitaria Senese
Siena, Italy
Blokhin National Medical Research Oncology Centre
Moscow, Russia
Branch Office of "Hadassah Medical Ltd"
Moscow, Russia
Moscow City Oncology Hospital #62
Moscow, Russia
LLC Medical Services
Saint Petersburg, Russia
Clinical Hospital Russian Railways - Medicine
Saint Petersburg, Russia
Petrov National Medical Research Center of Oncology
Saint Petersburg, Russia
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.